Note: Patient information, presentations and searches can be found in the overarching resource bulletin above.
The evidence to support the use of antioxidant vitamins to reduce the progression of age related macular degeneration is limited.
View > >
This bulletin supports a switch to the immediate release formulation.
View > >
Immediate release fentanyl has a NICE do not do as a first line treatment for breakthrough pain. This bulletin focuses on fentanyl immediate-release formulations.
View > >
There is limited evidence to support the use of glucosamine and chondroitin products and they are listed as a NICE do not do. This bulletin reviews the use of glucosamine (with or without chondroitin) preparations.
View > >
Herbal remedies
The MHRA allows herbal products to be marketed for minor health conditions that don’t require medical supervision, upon receipt of a Traditional Herbal Registration (THR). Claims to treat major health conditions are not allowed under a THR and would need a marketing authorisation. Under a THR there is no requirement to prove scientifically that a product works, the registration is based on longstanding use of the product. These products should be purchased as part of self care.
Homeopathic remedies
In 2010, a report by the House of Commons Science and Technology Committee found that the use of homeopathy was not evidence based and any benefits to patients was down to placebo effect.
This bulletin has been updated to reflect the latest national guidance on liothyronine and it's place in therapy. An audit tool, patient messages and PowerPoint presentation are available as supporting resources.
View > >
This bulletin looks at cost effective choices of needles and also advises on the appropriate use of safer sharps.
View > >
This bulletin provides information and resources to support deprescribing of these products which are considered low priority for prescribing and not cost-effective (with the exception of icosapent ethyl prescribed in line with NICE TA805).
View > >
This bulletin supports the review of oxycodone/naloxone prolonged release tablets, the rationale to stop treatment and also suggests alternative treatment options.
View > >
This bulletin was originally developed in May 2018, however as the price of perindopril erbumine was higher than perindopril arginine it was not published. The prices have now come down, but the savings are not as high as they previously were. The prices and references have been updated in this resource and it has been published for those commissioners who still wish to review prescribing.
View > >
This bulletin covers rubefacients and other miscellaneous topical analgesics. An audit, presentation and patient letter are available as supporting tools.
View > >
This bulletin supports the implementation of NHS England (NHSE) and the All Wales Medicines Strategy Group (AWMSG) guidance in relation to silk garments. Supporting data, infobriefs, an audit, GP clinical system searches, text message or letter templates and patient information leaflet are also available.
View > >
This bulletin focuses on Tramacet® (paracetamol 325mg/tramadol 37.5mg) and provides the rationale for new patients to be initiated on paracetamol or paracetamol with codeine.
View > >
This bulletin identifies those vaccines that should not be prescribed on the NHS for travel as well as offering advice on developing a local policy on travel vaccines.
View > >
Trimipramine is a tricyclic antidepressant (TCA) that has been subject to significant price increases. This bulletin reviews use with resources to support stopping or switching treatment in depression in adults.
View > >
